Global Hormone Refractory Breast Cancer Market

Hormone Refractory Breast Cancer Comprehensive Study by Treatment (Hormone receptor-based therapy, Tumor markers therapy, Gene expression therapy, Gene mutation therapy), End-users (Hospitals, Clinics, Ambulatory Surgical Centres, Others), Diagnosis (CT Scan, MRI, Biopsy, Others) Players and Region - Global Market Outlook to 2030

Hormone Refractory Breast Cancer Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hormone Refractory Breast Cancer
According to WHO, breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. In 2018, it is estimated that 627,000 women died from breast cancer that is approximately 15 of all cancer deaths among women as per world health organization. Breast cancer is cancer that forms a tumor in the cells of the breast. Hormone therapies are commonly used for the treatment of breast cancer, which subsequently leads to resistance after the continuous use of hormone therapy.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR8.5%


The global hormone refractory breast cancer market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hormone refractory breast cancer market. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Hormone Refractory Breast Cancer market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AstraZeneca plc (United Kingdom), Bluefish Pharmaceuticals AB (Sweden), AmpliMed Corporation (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland), Neopharm Ltd. (Israel), NeoCorp GmbH (Germany) and Boehringer Ingelheim GmbH (Germany) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Hormone Refractory Breast Cancer market by and Region.



On the basis of geography, the market of Hormone Refractory Breast Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Hormone receptor-based therapy will boost the Hormone Refractory Breast Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-users, the sub-segment i.e. Hospitals will boost the Hormone Refractory Breast Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. CT Scan will boost the Hormone Refractory Breast Cancer market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased Research and Development Activities and Government Initiatives for Cancer Research

Market Growth Drivers:
Increased Prevalence of Breast Cancer Worldwide and High Demand for Effective Cancer Treatment

Challenges:
Stringent Government Rules and Regulations

Restraints:
Less Awareness about Cancer Treatment in Some Regions

Opportunities:
Growth in the Health Care Industry and Huge Investments By Major Players

Market Leaders and their expansionary development strategies
On April 2022, Enhertu (trastuzumab deruxtecan), a collaboration between AstraZeneca and Daiichi Sankyo, has received Breakthrough Therapy Designation (BTD) in the United States for the treatment of adults with metastatic HER2-low breast cancer who have gone through prior systemic therapy in the metastatic setting or who have developed disease re-occurrence during or within six months of completing adjuvant chemotherapy. The therapy can be applied to patients having hormone receptor-positive breast cancer should have had endocrine therapy else they are ineligible for it. AstraZeneca and Daiichi Sankyo are working to develop and commercialize Enhertu, a precisely tailored HER2-directed antibody-drug conjugate (ADC).
In February 2023, Gilead Sciences, Inc. announced the U.S. Food and Drug Administration (FDA) has approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.


Key Target Audience
Pharmaceutical Companies, Raw Material Suppliers, Distributors, Emerging Companies and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Treatment
  • Hormone receptor-based therapy
  • Tumor markers therapy
  • Gene expression therapy
  • Gene mutation therapy

By End-users
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Others

By Diagnosis
  • CT Scan
  • MRI
  • Biopsy
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Breast Cancer Worldwide
      • 3.2.2. High Demand for Effective Cancer Treatment
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
      • 3.4.2. Government Initiatives for Cancer Research
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hormone Refractory Breast Cancer, by Treatment, End-users, Diagnosis and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hormone Refractory Breast Cancer (Value)
      • 5.2.1. Global Hormone Refractory Breast Cancer by: Treatment (Value)
        • 5.2.1.1. Hormone receptor-based therapy
        • 5.2.1.2. Tumor markers therapy
        • 5.2.1.3. Gene expression therapy
        • 5.2.1.4. Gene mutation therapy
      • 5.2.2. Global Hormone Refractory Breast Cancer by: End-users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Ambulatory Surgical Centres
        • 5.2.2.4. Others
      • 5.2.3. Global Hormone Refractory Breast Cancer by: Diagnosis (Value)
        • 5.2.3.1. CT Scan
        • 5.2.3.2. MRI
        • 5.2.3.3. Biopsy
        • 5.2.3.4. Others
      • 5.2.4. Global Hormone Refractory Breast Cancer Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Hormone Refractory Breast Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bluefish Pharmaceuticals AB (Sweden)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AmpliMed Corporation (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Neopharm Ltd. (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. NeoCorp GmbH (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Boehringer Ingelheim GmbH (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Hormone Refractory Breast Cancer Sale, by Treatment, End-users, Diagnosis and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hormone Refractory Breast Cancer (Value)
      • 7.2.1. Global Hormone Refractory Breast Cancer by: Treatment (Value)
        • 7.2.1.1. Hormone receptor-based therapy
        • 7.2.1.2. Tumor markers therapy
        • 7.2.1.3. Gene expression therapy
        • 7.2.1.4. Gene mutation therapy
      • 7.2.2. Global Hormone Refractory Breast Cancer by: End-users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Ambulatory Surgical Centres
        • 7.2.2.4. Others
      • 7.2.3. Global Hormone Refractory Breast Cancer by: Diagnosis (Value)
        • 7.2.3.1. CT Scan
        • 7.2.3.2. MRI
        • 7.2.3.3. Biopsy
        • 7.2.3.4. Others
      • 7.2.4. Global Hormone Refractory Breast Cancer Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hormone Refractory Breast Cancer: by Treatment(USD Million)
  • Table 2. Hormone Refractory Breast Cancer Hormone receptor-based therapy , by Region USD Million (2018-2023)
  • Table 3. Hormone Refractory Breast Cancer Tumor markers therapy , by Region USD Million (2018-2023)
  • Table 4. Hormone Refractory Breast Cancer Gene expression therapy , by Region USD Million (2018-2023)
  • Table 5. Hormone Refractory Breast Cancer Gene mutation therapy , by Region USD Million (2018-2023)
  • Table 6. Hormone Refractory Breast Cancer: by End-users(USD Million)
  • Table 7. Hormone Refractory Breast Cancer Hospitals , by Region USD Million (2018-2023)
  • Table 8. Hormone Refractory Breast Cancer Clinics , by Region USD Million (2018-2023)
  • Table 9. Hormone Refractory Breast Cancer Ambulatory Surgical Centres , by Region USD Million (2018-2023)
  • Table 10. Hormone Refractory Breast Cancer Others , by Region USD Million (2018-2023)
  • Table 11. Hormone Refractory Breast Cancer: by Diagnosis(USD Million)
  • Table 12. Hormone Refractory Breast Cancer CT Scan , by Region USD Million (2018-2023)
  • Table 13. Hormone Refractory Breast Cancer MRI , by Region USD Million (2018-2023)
  • Table 14. Hormone Refractory Breast Cancer Biopsy , by Region USD Million (2018-2023)
  • Table 15. Hormone Refractory Breast Cancer Others , by Region USD Million (2018-2023)
  • Table 16. South America Hormone Refractory Breast Cancer, by Country USD Million (2018-2023)
  • Table 17. South America Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 18. South America Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 19. South America Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 20. Brazil Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 21. Brazil Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 22. Brazil Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 23. Argentina Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 24. Argentina Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 25. Argentina Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 26. Rest of South America Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 27. Rest of South America Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 28. Rest of South America Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 29. Asia Pacific Hormone Refractory Breast Cancer, by Country USD Million (2018-2023)
  • Table 30. Asia Pacific Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 31. Asia Pacific Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 32. Asia Pacific Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 33. China Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 34. China Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 35. China Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 36. Japan Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 37. Japan Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 38. Japan Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 39. India Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 40. India Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 41. India Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 42. South Korea Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 43. South Korea Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 44. South Korea Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 45. Taiwan Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 46. Taiwan Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 47. Taiwan Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 48. Australia Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 49. Australia Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 50. Australia Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 54. Europe Hormone Refractory Breast Cancer, by Country USD Million (2018-2023)
  • Table 55. Europe Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 56. Europe Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 57. Europe Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 58. Germany Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 59. Germany Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 60. Germany Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 61. France Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 62. France Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 63. France Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 64. Italy Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 65. Italy Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 66. Italy Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 67. United Kingdom Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 68. United Kingdom Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 69. United Kingdom Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 70. Netherlands Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 71. Netherlands Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 72. Netherlands Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 73. Rest of Europe Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 74. Rest of Europe Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 75. Rest of Europe Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 76. MEA Hormone Refractory Breast Cancer, by Country USD Million (2018-2023)
  • Table 77. MEA Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 78. MEA Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 79. MEA Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 80. Middle East Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 81. Middle East Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 82. Middle East Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 83. Africa Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 84. Africa Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 85. Africa Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 86. North America Hormone Refractory Breast Cancer, by Country USD Million (2018-2023)
  • Table 87. North America Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 88. North America Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 89. North America Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 90. United States Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 91. United States Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 92. United States Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 93. Canada Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 94. Canada Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 95. Canada Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 96. Mexico Hormone Refractory Breast Cancer, by Treatment USD Million (2018-2023)
  • Table 97. Mexico Hormone Refractory Breast Cancer, by End-users USD Million (2018-2023)
  • Table 98. Mexico Hormone Refractory Breast Cancer, by Diagnosis USD Million (2018-2023)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Hormone Refractory Breast Cancer: by Treatment(USD Million)
  • Table 107. Hormone Refractory Breast Cancer Hormone receptor-based therapy , by Region USD Million (2025-2030)
  • Table 108. Hormone Refractory Breast Cancer Tumor markers therapy , by Region USD Million (2025-2030)
  • Table 109. Hormone Refractory Breast Cancer Gene expression therapy , by Region USD Million (2025-2030)
  • Table 110. Hormone Refractory Breast Cancer Gene mutation therapy , by Region USD Million (2025-2030)
  • Table 111. Hormone Refractory Breast Cancer: by End-users(USD Million)
  • Table 112. Hormone Refractory Breast Cancer Hospitals , by Region USD Million (2025-2030)
  • Table 113. Hormone Refractory Breast Cancer Clinics , by Region USD Million (2025-2030)
  • Table 114. Hormone Refractory Breast Cancer Ambulatory Surgical Centres , by Region USD Million (2025-2030)
  • Table 115. Hormone Refractory Breast Cancer Others , by Region USD Million (2025-2030)
  • Table 116. Hormone Refractory Breast Cancer: by Diagnosis(USD Million)
  • Table 117. Hormone Refractory Breast Cancer CT Scan , by Region USD Million (2025-2030)
  • Table 118. Hormone Refractory Breast Cancer MRI , by Region USD Million (2025-2030)
  • Table 119. Hormone Refractory Breast Cancer Biopsy , by Region USD Million (2025-2030)
  • Table 120. Hormone Refractory Breast Cancer Others , by Region USD Million (2025-2030)
  • Table 121. South America Hormone Refractory Breast Cancer, by Country USD Million (2025-2030)
  • Table 122. South America Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 123. South America Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 124. South America Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 125. Brazil Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 126. Brazil Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 127. Brazil Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 128. Argentina Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 129. Argentina Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 130. Argentina Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 131. Rest of South America Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 132. Rest of South America Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 133. Rest of South America Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 134. Asia Pacific Hormone Refractory Breast Cancer, by Country USD Million (2025-2030)
  • Table 135. Asia Pacific Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 136. Asia Pacific Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 137. Asia Pacific Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 138. China Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 139. China Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 140. China Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 141. Japan Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 142. Japan Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 143. Japan Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 144. India Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 145. India Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 146. India Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 147. South Korea Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 148. South Korea Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 149. South Korea Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 150. Taiwan Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 151. Taiwan Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 152. Taiwan Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 153. Australia Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 154. Australia Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 155. Australia Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 159. Europe Hormone Refractory Breast Cancer, by Country USD Million (2025-2030)
  • Table 160. Europe Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 161. Europe Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 162. Europe Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 163. Germany Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 164. Germany Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 165. Germany Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 166. France Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 167. France Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 168. France Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 169. Italy Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 170. Italy Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 171. Italy Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 172. United Kingdom Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 173. United Kingdom Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 174. United Kingdom Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 175. Netherlands Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 176. Netherlands Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 177. Netherlands Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 178. Rest of Europe Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 179. Rest of Europe Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 180. Rest of Europe Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 181. MEA Hormone Refractory Breast Cancer, by Country USD Million (2025-2030)
  • Table 182. MEA Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 183. MEA Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 184. MEA Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 185. Middle East Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 186. Middle East Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 187. Middle East Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 188. Africa Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 189. Africa Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 190. Africa Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 191. North America Hormone Refractory Breast Cancer, by Country USD Million (2025-2030)
  • Table 192. North America Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 193. North America Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 194. North America Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 195. United States Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 196. United States Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 197. United States Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 198. Canada Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 199. Canada Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 200. Canada Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 201. Mexico Hormone Refractory Breast Cancer, by Treatment USD Million (2025-2030)
  • Table 202. Mexico Hormone Refractory Breast Cancer, by End-users USD Million (2025-2030)
  • Table 203. Mexico Hormone Refractory Breast Cancer, by Diagnosis USD Million (2025-2030)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hormone Refractory Breast Cancer: by Treatment USD Million (2018-2023)
  • Figure 5. Global Hormone Refractory Breast Cancer: by End-users USD Million (2018-2023)
  • Figure 6. Global Hormone Refractory Breast Cancer: by Diagnosis USD Million (2018-2023)
  • Figure 7. South America Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 8. Asia Pacific Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 9. Europe Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 10. MEA Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 11. North America Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 12. Global Hormone Refractory Breast Cancer share by Players 2023 (%)
  • Figure 13. Global Hormone Refractory Breast Cancer share by Players (Top 3) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. AstraZeneca plc (United Kingdom) Revenue: by Geography 2023
  • Figure 17. Bluefish Pharmaceuticals AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 18. Bluefish Pharmaceuticals AB (Sweden) Revenue: by Geography 2023
  • Figure 19. AmpliMed Corporation (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. AmpliMed Corporation (United Kingdom) Revenue: by Geography 2023
  • Figure 21. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 23. Neopharm Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 24. Neopharm Ltd. (Israel) Revenue: by Geography 2023
  • Figure 25. NeoCorp GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 26. NeoCorp GmbH (Germany) Revenue: by Geography 2023
  • Figure 27. Boehringer Ingelheim GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Boehringer Ingelheim GmbH (Germany) Revenue: by Geography 2023
  • Figure 29. Global Hormone Refractory Breast Cancer: by Treatment USD Million (2025-2030)
  • Figure 30. Global Hormone Refractory Breast Cancer: by End-users USD Million (2025-2030)
  • Figure 31. Global Hormone Refractory Breast Cancer: by Diagnosis USD Million (2025-2030)
  • Figure 32. South America Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 33. Asia Pacific Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 34. Europe Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 35. MEA Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 36. North America Hormone Refractory Breast Cancer Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca plc (United Kingdom)
  • Bluefish Pharmaceuticals AB (Sweden)
  • AmpliMed Corporation (United Kingdom)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Neopharm Ltd. (Israel)
  • NeoCorp GmbH (Germany)
  • Boehringer Ingelheim GmbH (Germany)
Select User Access Type

Key Highlights of Report


Mar 2024 217 Pages 81 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hormone Refractory Breast Cancer Market Quantitative research analysis
Global Hormone Refractory Breast Cancer Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AstraZeneca plc (United Kingdom), Bluefish Pharmaceuticals AB (Sweden), AmpliMed Corporation (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland), Neopharm Ltd. (Israel), NeoCorp GmbH (Germany) and Boehringer Ingelheim GmbH (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased Research and Development Activities " is seen as one of major influencing trends for Hormone Refractory Breast Cancer Market during projected period 2023-2030.
The Hormone Refractory Breast Cancer market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hormone Refractory Breast Cancer Market Report?

Have a Query? Click Here

Other Related Reports

Refsum Disease Treatment Comprehensive Study by Type (Surgery Therapy, Medication), Application (Hospitals, Clinics, Others), Diagnosis (Physical, Molecular Genetic Examination, Prenatal Screening, E...
$ 3350
Trauma Care Center Comprehensive Study by Facility Type (In-house, Standalone), Trauma Type (Falls, Traffic-Related Injuries, Stab/Wound/Cut, Burn Injury, Brain Injury, Other Injuries), Service Type ...
$ 3350
Nephroblastoma Treatment Comprehensive Study by Drugs (Dactinomycin, Doxorubicin,, Vincristine, Cyclophosphamide, Etoposide), Treatment (Surgery, Chemotherapy, Radiation therapy), End-users (Hospital...
$ 3750
Staphylococcal Infection Drugs Comprehensive Study by Type (Beta-lactams, Peptides, Quinolones, Others), Application (Hospital, Pharmacy, Others), Treatment (Antibiotics, Wound Drainage, Device Remov...
$ 3450
Hepatorenal Syndrome Treatment Comprehensive Study by Type (Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome), Treatment (Therapeutics (Terlivaz, Glypressin, Lucassin, Hepatoren), Surgical Tr...
$ 3750
Heatstroke Treatment Comprehensive Study by Type (Exertional Heat Stroke, Non-Exertional Heat Stroke), Drugs (Dantrolene, Midazolam, Clonidine, Meperidine, Others), Route of Administration (Oral, Par...
$ 3750